Head and neck squamous cell carcinoma patients have been characterized by impairments in their cell-mediated immune system, particularly by decreased chemotactic function of monocytes and impairments in the function of the monocyte-derived dendritic cells (viz, a decreased capability to form cell "clusters"). These impairments are thought to be due to immunosuppressive factors of low molecular mass released by tumor, the socalled pl5E-like factors. These suppressive effects of pl5-1ike factors can be neutralized in vitro by thymic peptides, such as thymostimulin (TP1). In a randomized double-blind, placebo-controlled multicenter trial in the Netherlands, 41 patients with operable head and neck squamous cell carcinomas (HNSCC) were treated for 10 days prior to surgery with intramuscular TP1 in one of three dosages (0.5 mg/kg; 1.0 rng/kg or 2.0 mg/kg body weight) or treated with placebo. Assessment of monocyte chemotaxis, the capability of dendritic cells to form clusters and the presence of pl5E-like low-molecular-mass factors (LMMFs) in serum was performed before TP1 treatment and on the day of surgery. Findings demonstrated that TP1 in a dose of 1.0 mg/kg and 2.0 mg/kg resulted in normalization of impaired monocyte chemotactic capability. Although the cluster capability of dendritic cells after TP1 treatment improved, values only reached statistical significance for the 0.5 mg/kg group. Serum pl5E-like LMMF levels were Contrary to expectations we found no correlation between elevated immunosuppressive LMMFs and defective monocyte chemotaxis or cluster capability of dendritic cells. We conclude that treatment with TP1 can improve monocyte chemotaxis in HNSCC patients but an effect on the production of pl5E-like factors by carcinoma cells could not be demonstrated.
Introduction
Patients with head and neck squamous cell carcinoma (HNSCC) may show certain deficits in their immune functions. The cell-mediated immune system is particularly affected with defects including T-cell function [20, 24, 44] , and impaired function of monocytes, monocyte-derived dendritic cells and macrophages [3, 5, 8, 14, 16, 37, 43, 45] .
We and others have previously reported in detail impairments of blood monocyte chemotaxis in HNSCC patients. These monocyte chemotactic defects are thought to be caused by factors of low molecular mass (LMMFs, < 25 kDa) produced by the cancer cells and appearing in the sera of affected patients. These chemotactic defects can be mimicked in vivo in animal models as well as in vitro using healthy donor monocytes exposed to such tumor-isolated LMMFs [4, 36, 38] . Since LMMFs show a structural and functional homology with transmembrane (TM) protein p 15E of animal leukemogenic retroviruses, these substances are therefore generally be referred to as "immunosuppressive p 15E-like-or TM-like LMMFs" [9, 38] .
The function of monocyte-derived, antigen-presenting dendritic cells is frequently disturbed in the presence of HNSCC. This defect may also be the result of pl5E-like LMMFs [43] , since such factors in vitro exert a negative effect on the ability of dendritic cells to form cellular clusters. In general, monocyte-derived dendritic cells are class II MHC-positive mononuclear cells with long cytoplas-mic extensions that act as excellent accessory cells in immune responses [2, 13, 19, 26, 35] .
In an earlier report we demonstrated that abnormal monocyte chemotaxis and a defective cluster capability of dendritic cells could be restored in vitro by the addition of a thymic peptide preparation called thymostimulin (TP1) [43] . Clinical trials investigating the effect of TP1 in various malignant disorders have since been carried out. Tlymphocyte levels were found to increase in patients with malignant melanomas and clinical outcomes could be improved with adjuvant TP1 treatment [7] . In cases with large head and neck cancers overall response to chemotherapy improved if TP1 was used as adjuvant therapy [34] , while peripheral T-cell counts improved under the influence of TP1 in patients with Hodgkin's disease [25] . These various observations were the impetus for us to conduct a double-blind, placebo-controlled multicenter study to define in vivo effects of TP1 treatment on monocyte chemotactic functions, cluster capability of dendritic cells and levels of serum pl5E-like factors in HNSCC patients.
Patients and methods
Forty-one patients with operable squamous cell carcinoma of the oral cavity, oropharynx, hypopharynx or larynx agreed to participate in the trial. All patients met the inclusion criteria listed in Table 1 and gave informed consent according to university requirements for human research in The Netherlands. All patients were entered randomly in a double-blind fashion in one of the four following treatment groups: group I -patients receiving placebo treatment; group II -patients receiving 0.5 mg/kg TP1; group IIIpatients receiving 1.0 mg/kg TP1; group IV -patients receiving 2.0 mg/kg TP1. To avoid investigator bias, TP1 in different dosages or placebo was (double-blind) injected intramuscularly in each patient once daily for 10 consecutive days prior to definitive operation. All injections were well tolerated and no adverse side effects were seen. Table 2 summarizes the patients' ages and sexes, tumor locations and differentiations, TNM classification and subsequent treatment given• No statistical differences were found for age, TNM classification or tumor differentiations.
Bovine thymic extract (TP1)
Thymostimulin was prepared as a bovine thymic extract using the following procedure described by Bergesi and Falchetti [6] and Table 1 Inclusion criteria for patients with operable head and neck squamous cell carcinomas (HNSCC) for determining effects of TP1 treatment on monocyte polarization, dendritic cell clustering and serum p15E-like transmembrane factors Falchetti et al. [ 12] . Calf thymus glands were minced and extracted with ammonium acetate. The extract was then heated to 70 ° C, filtered, and precipitated with ammonium sulfate• The precipitate was dissolved in water and subjected to ultrafiltration on an Ami- [12] . Additionally, the extract failed to alter neuromuscular transmission in vitro or in vivo [6] .
Isolation of peripheral blood monocytes
Peripheral blood mononuclear ceils from patients and healthy controls were isolated by Ficoll-Isopaque density gradient centrifugation. Cells were washed twice in phosphate buffered saline (PBS) at pH 7.4, containing 0.5% bovine serum albumin (BSA). Cells were then counted in suspension employing positive staining with non-specific esterase (NSE) as described by Mullink et al. [29] . Monocytes in the Ficoll-Isopaque isolated fraction were enriched by Percoll gradient centrifugation [31] . After washing, the Ficollisolated cell pellet containing both monocytes and lymphocytes was resuspended in RPMI 1640 supplemented with 10% fetal calf serum (GIBCO, Breda, The Netherlands), 2 mM glutamine and antibiotics (penicillin and streptomycin), and carefully underlaid with an equal volume of Percoll 1.063 (Pharmacia, Uppsala, Sweden). After centrifugation at 400 g for 40 min, all cells were collected from the interface, washed twice in medium for 10 min and counted. This latter suspension now contained 70-95% NSE-posirive cells. This suspension was used for direct monocyte polarization and maturation to obtain dendritic cells (see below).
Formation of dendritic cells
Dendritic cells were prepared from blood monocytes according to the method described by Kabel et al. [21] . Metrizamide (Serva, Heidelberg, Germany) was dissolved in RPMI supplemented with 10% fetal calf sea-um. Cells from the isolated monocyte fractions were exposed to 14.5% metrizamide in suspension culture for 30 min (using 5% CO2 at 37°C and 100% humidity). Thereafter, cells were washed by slowly adding culture fluid to prevent osmotic lysis. Cells were then further cultured under non-adhering conditions for 16 h in polypropylene tubes (with 5% CO2 and 100% humidity at 37 ° C). This procedure yielded 40-80% cells with a dendritic morphology, showing class II MHC positivity, decreased expression of the monocytic CD14 determinant, decreased phagocytic capability, but enhanced stimulator capability in the mixed leukocyte reaction (MLR). The full technical details of this method are described by Kabel et al. [21] and in Mooy et al. [28] .
Clustering of dendritic cells
The cluster assay as described by Austyn et al. [2] was performed with modifications used by Kabel et al. [21] . Approximately 5 x 10 ~ dendritic cells prepared from peripheral blood monocytes were exposed to metrizamide and allowed to cluster for 4 h in 5% CO2 at 37°C in 250 gl flat-bottomed wells. Formed clusters were counted using an inverted microscope and values were expressed as the number of clusters per 6 microscopic fields (x 200). A cluster was defined as an accumulation of 4-25 cells in three-dimensional configuration. An insufficient amount of blood was received to obtain enough dendritic cells for the cluster assay in 8 cases.
correlate well with outcomes of the conventional Boyden chamber assay to measure chemotaxis to casein [38] Lymphocytes were excluded by their lack of any polarization activity in this assay [9] .
Determination of p15E-like immunosuppressive factors in patients' sera Sera for immunological evaluation was collected by venipuncture prior to the first injection of TP1 and 1-2 h before surgery. In a number of events insufficient sera were received due to logistical problems. Sera of healthy hospital staff members served as control sera during all tests. Sera were diluted 1 : 1 in saline and subjected to ultrafiltration through Amicon CD25 Centriflo cones (Amicon Corp., Danvers, Maine, USA) for 15 rain at 800 g (molecular mass "cut-off point", 25 kDa). Residues were resuspended and stored at -20 ° C until further use,
The capability of serum fractions to inhibit fMLP-induced polarization of healthy donor (elutriator-purified) monocytes was determined by incubating (1 x 106/ml) healthy donor monocytes for 15 min at 37°C either with fMLP alone or with fMLP in combination with a serum fraction (final dilution, 1:60). Details of the technique have been described by Tas et al. [43] . The percentage of inhibition was calculated as follows: i = (1 -(Ff-fo/Mf-fo)) × 100%, where Ff = % monocytes polarized after incubation with fMLP and LMMF; Mf = % monocytes polarized after incubation with fMLP alone; and fo = % spontaneously polarized monocytes.
Spontaneous polarization was not affected by addition of serum fractions to non-fMLP stimulated donor monocytes.
To validate the p 15E-like character of LMMF adsorption, experiments were carried out by neutralizing serum fractions at 4°C for 16 h before testing effects on monocyte polarization by using a combination of two pl5E-specific mAbs (4F5 and 19F8 as antipl5E isotypes IgG2a and IgG2b). The final mAb dilution was 1 : 200 and final IgG concentration 50 gg/ml. Following neutralization, Amicon ultrafiltration was performed to remove complexes. The adsorption/neutralizing procedure was carried out twice. As control antibodies irrelevant anti-human IgG2a and IgG2b were used.
Statistical analysis
Monocyte polarization assay Statistical analysis was performed using the Wilcoxon signed rank test; P < 0.05 was taken as the level of significance.
The Cianciolo and Snyderman [10] assay for monocyte polarization was performed with slight modifications [38] to rapidly test monocyte chemotaxis. Outcomes of the assay previously proved to 
Results
Defects of monocyte polarization and dendritic cell clustering capability in relation to serum pl5E-like LMMF levels Figure 1 shows pretreatment levels of p15E-like LMMFs in the sera of individual HNSCC patients in comparison to their individual monocyte chemotactic capabilities, Levels of pl5E-like LMMFs in patient sera were determined indirectly by measuring their suppressive effects on fMLP-induced monocyte polarization of healthy blood donors.
In the control group of healthy volunteers the mean monocyte polarization was 34.2% + 7.9 (n = 23), while the mean bioactive inhibitory level of pl5E-like LMMFs was 7.3% 5:9.3 (n = 23). Monocyte polarization < 18.4% (mean -2 SD) was therefore considered to be defective, and LMMF levels > 25.9% inhibition (mean + 2 SD) were considered elevated. According to these criteria, 16 patients (40%) had defective monocyte polarization, viz chemotaxis of lower than 18.4% towards the chemoattractant fMLP prior to treatment. Twelve patients (31%) had elevated pl5E-like LMMF levels. The patients with defective monocyte chemotaxis were evenly distributed over the group that had normal serum LMMF levels and the group that had elevated serum LMMF levels, and no correlation was possible between elevated LMMF levels and disturbed monocyte chemotactic capability (n = 35, 1" = 0.018, P > 0.1).
The mean dendritic cell cluster assay in the healthy controls was 133.5 + 42 clusters/6 microscopic fields (n = 17). A value of less than 92 clusters/6 microscopic fields (mean -1 SD) was considered to be abnormal. According to this criterion 16 patients had defective dendritic cell clustering capability before treatment. A correlation between dendritic cell clustering capability and pl5E-like LMMF levels could not be detected (n = 34, r = -0.10, P > 0.5). Furthermore no correlation existed between dendritic cell clustering capability and monocyte polarization (n = 34, r --0.08, P > 0.5).
Effects of TP1 treatment on monocyte polarization, dendritic cell clustering capability and serum pl5E-like LMMF levels Figure 2a shows fMLP-induced polarization of monocytes isolated from the blood of HNSSC patients before surgery (day 0) and 10 days after surgery (day 10) and administration of either placebo or a TP1 dosage. In all four groups the mean initial value (day 0) was markedly lower than the 34.2% mean of the polarized monocytes found in the healthy control group.
Treatment with 1.0 mg/kg TP1 resulted in a restoration of disturbed monocyte polarization from 17.6% + 6.3 (n = 13) to a near-normal value of 30.9% + 13.8 (n = 13) at day 10 (P < 0.01). Similar effects were seen with 2.0 mg/kg TP1 (P < 0.05). Monocyte polarization improved to 32.0% + 15.8 (n = 9) from an initial 17.8% + 18.2 (n = 9). Treatment with 0.5 mg/kg TP1 showed no significant improvement (20.9% + 7.0 to 23.0% + 8.1, n = 10). Placebo treatment also showed no significant effect on the impaired monocyte polarization (24.0% + 14.2 to 25.7% + 8.3, n = 9). Figure 2b shows the number of clusters formed by monocyte-derived dendritic cells from the sera of HNSSC patients. At day 0, patients of all four groups showed lower values than normal, although this was least marked for the placebo group. All three TPl-treated groups showed an increase in mean dendritic cell clustering capability after treatment (0. group reached statistical significance (P < 0.05). The placebo group showed some decrease in the clustering capability of dendritic cells, but this decrease was not statistically significant. Pretreatment levels of pl5E-like LMMFs and values found after 10 days of TP1 treatment are shown in Fig. 2c . No significant changes were found in the levels of serum pl5E-like factors in group I (0.5 mg/kg, n = 7), group II (1.0 mg/kg, n = 15), group III (2.0 mg/kg, n = 9) or placebo (n = 9).
Discussion
Suppression of cell-mediated immunity in HNSCC is thought to be at least partially due to immunosuppressive LMMFs produced and released by tumors [9] . These factors show a structural homology to retroviral protein pl5E. The pl5E-like LMMFs and a 17-amino-acid peptide synthesized from MuLV pl5E (anti-CKS-17) exert a suppressive effect on various immune cells. Suppression has been demonstrated in vitro on monocyte chemotactic responses [9, 36] ; monocyte cytotoxicity by inactivating interleukin-1 (IL-1) [15, 22] ; the respiratory burst of human monocytes [17] ; activation of feline neutrophils [23] ; IL-2-or IL-l-dependent proliferations of T-cells and their blastogenic responses to mitogens and allo-antigens [11, 30, 33] , activity of human natural killer (NK) cells [18] ; polyclonal activation of B-cells [27] and the capability of dendritic cells to form clusters per se and with T-cells [32, 41] .
The presence of immunosuppressive pl5E-like factors can be detected in the serum of HNSCC patients via a bioassay using healthy donor monocytes. In previous studies we showed that removal of a tumor often resulted in a postoperative decline of the level of these serum pl5E-like LMMFs [42] , and restoration of monocyte chemotactic responsiveness [36] . We assumed that there was a direct effect on monocyte chemotaxis by immunosuppressive pl5E-like LMMFs produced by tumor and circulating in serum, since direct contact between monocytes and the serum pl5E-like factors seemed inevitable. Our present data, however, have failed to demonstrate any positive correlations between defective monocyte chemotaxis or dendritic cell clustering and serum levels of p 15E-like LMMFs.
An explanation for our present findings may be due to heterogeneity in sensitivity of monocytes of individual HNSCC patients to immunosuppressive effects of pl5E-like factors. It is also possible that other immunomodulating factors produced in our patients and stimulating or suppressing monocyte chemotaxis may play an additional role. A third explanation might be that defective monocyte polarization and dendritic cell clustering might not be a direct result of elevated p 15E-like LMMFs in serum, but that these immunosuppressive factors could possibly exert such effects as hampered maturation of fully active monocytes and dendritic cells at the level of the bone marrow. In contrast, healthy individuals may have relatively high serum levels of pl5E-like LMMFs without showing clinical or experimental signs of immune suppression [39] .
Our results do show restoration of defective monocyte chemotactic responsiveness in HNSCC patients due to treatment with TP1. Treatment with 1.0 mg/kg or 2.0 mg/kg body weight administered intramuscularly for 10 consecutive days prior to operation has given near-normal values for monocyte responsiveness on the day of operation. Statistically, 1.0 mg/kg was found to be the most optimal dose for restoration of the monocyte polarization, which has also been reported to be the dose most frequently used to treat patients with various other disorders [1, 7, 40] . An improvement of the dendritic cell clustering capability after TP1 treatment was seen for all TP1-treated groups; however only in the 0.5 mg/kg group did this reach statistical significance. A plausible explanation for this may be that the mean pretreatment values of the dendritic cell cluster assay of the 1.0 mg/kg and 2.0 mg/kg groups were less disturbed than those of the 0.5 mg/kg group. Therefore the possible improvement that could be achieved was less pronounced. Tas et al. [40] treated patients with chronic purulent rhinosinusitis and found a similar restorative effect of TP1 treatment on monocyte chemotactic functions accompanied by a concomitant decrease in serum p 15E-like LMMF levels as well as clear clinical improvement.
In our current study, pl5E-like LMMF levels in sera from HNSCC patients were unaffected by TP1 treatment. These findings suggest that TP1 counteracts the immunosuppressive effects of pl5E-like factors at a cellular level and TP1 does not affect production of pl5E-like factors by tumor. The decrease in detectable serum LMMF levels reported in patients with rhinosinusitis after TP1 treatment could also be explained by a lower production due to improved clinical status, rather than a direct effect of TP1 on the production or immunosuppressive properties of these pl5E-like LMMFs. Conclusions concerning clinical effects of TP1 in the treatment of HNSCC cannot be drawn from our study at this time and will be addressed in a later report on the long-term results of TP1 treatment.
